PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MIBC COMPRISING INHIBITOR OF S100A9 AND EGFR AND CISPLATIN AS EFFECTIVE COMPONENTS

摘要

The present invention relates to a method for predicting probability of recurrence or metastasis of muscle infiltrative bladder cancer (MIBC), a method for providing information on a personalized medicine of the MIBC, and a pharmaceutical composition for treating MIBC comprising inhibitors of S100A9 and EGFR and a cisplatin as active components. According to the present invention, a precise prediction of prognosis after a chemotherapy treatment on a MIBC patient is enabled, and information on sensitivity for the cisplatin can be provided in terms of providing the personalized medicine for the chemotherapy treatment on the MIBC patient. Furthermore, a combined treatment of the existing cisplatin and the inhibitors of S100A9 and EGFR increases the sensitivity toward the cisplatin of the MIBC patient.